谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1–Monotherapy Pretreated, Advanced NSCLC: Results from a Phase 1b Clinical Trial

Edward B. Garon,Alexander I. Spira,Sarah B. Goldberg,Jamie E. Chaft,Vassiliki Papadimitrakopoulou,Tina Cascone,Scott J. Antonia,Julie R. Brahmer,Ross Camidge,John D. Powderly,Antoinette J. Wozniak,Enriqueta Felip, Song Wu,Maria L. Ascierto,Nairouz Elgeioushi,Mark M. Awad

JOURNAL OF THORACIC ONCOLOGY（2023）

引用 0|浏览32
关键词
Durvalumab,Tremelimumab,Combination ther-apy,Immunotherapy,Non-small cell lung cancer
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要